few on fourth joining everyone. Thanks review as Thanks, with our quarter Paul and along aannouncements we for today’s us recent call highlights. morning, good a
gratitude Genocea the vaccine GEN-XXX and this in patients. have to clinics pivot me That off for momentum and lead our agility and into pride neoantigen they has into affecting our cancer in by expressing team getting demonstrated tenacity the continued the start strategic in Let my to and year.
this that our new our CFO. morning, us Meisner, I Medical; and you Aakalu As we earlier leadership Counsel; our Derek Duvall say I is team the additions. entire joining to and General our Diantha saw be happier announced Tom I Chief And as She have recent Davis, team joins hope Chief Girish Business Officer couldn’t here. team as assembling leadership our with indeed we're
an GEN-XXX trial. had Now forward our let's to company enrollment with earlier, important that dosing turn seeing And early as Genocea study clinical our immuno-oncology first in progress we relaunched and efforts. an just to and of in pleased pace data immunogenicity look from the Phase reached X/Xa January, this first given recent months our of attention we're A mid-XXXX. the XX In patients completing Genocea milestone Part this very
compelling Atlas SITC also November. the We data at meeting presented last
antigen pre-existing for which responses For identify [purity specific of mutation. rather opposite and promoting. those which providing we our responses system Atlas to tumor to against therefore occurred a data right presented model is them. Using a inhibitory both contrasts note This on us the single also with to the and machine the proprietary new profile based positive to responses, responses as educated Atlas direct of the personalized our neoantigens but every antigen clinical amplify what we as incorrectly. as predict in know trial guess] well response both of information immune to that away immune with than neoantigens about Unlike and evidence injected available want neoantigens that mouse T immune we a I tumor and you the we who neoantigen could may we personalized these Atlas our to perform those inhibitory with profile, not CDX where just a cell we call make of that makes platform selection, neoantigens appear At suppress concentrate immune efficacy. each we enables CDA patient and doing melanoma from that that enables story wish SITC, us GEN-XXX be believe be each broadly inhibitory injected systems new responses guesses based We and antitumor only caused neoantigens tumor identification growth. patient. tumor to should antitumor identified mice we're this in evidence
to of inhibitors, We also as biological response help words presented frequency tumor better predict in use well regardless checkpoint and readouts data burden. new indicating the therapy better checkpoint may robust enable other mutational therapies. as may cell the their vaccines of patient's of neoantigens inhibitor insure inhibitory relative Atlas's
approach program CDX, patient we from cell would responses. as PBMCs research we Last at and Atlas the making our in to we than provide continue the a both greater Rather cell to program, both tumor responding a advantages the now. identify to to helpers could these efficacy treatment. exciting cells neoantigens the inhibitory through and scientific of presentations such several The methodologies. of Atlas. lastly inclusion medical tumor T improve T forward inclusion of a meetings. CDX in perhaps GEN-XXX against for patient little vaccine of dozens immunogenicity quarter, multiple with CDX patient's the on and own We therapeutic patient's T over will levels look isolate types of therapy cells program ramped on of we speed the manufacturing. safety cells efficacy ACT T T types additional including or or like to nonengineered killer those current instead back approaches and neoantigens neoantigens specific adoptive are escape. that provide and neoantigens introduction provide TIL more cell effect a cells believe in own of identified our our T GEN-XXX exploratory antigen of mitigate ACT areas expand such and upcoming risk Using detail as which exclusion up therapy antitumor broaden investment We CDX specific cost GEN-XXX to and using as neoantigen therapy and TCR to And of which a in to potential could GEN-XXX In through also potent we antitumor greater variety
are efforts We and GENXXX to an aim XXXX. half currently of in the conducting preclinical first of IND file
call briefly turn up before financial opening let's questions. Now to our the to results
As and cash release, detailed quarter ended fourth million. in the cash press of $XX.X we today's with equivalents
us ago. be and to $XX runway raised scale In to we GENXXX noted in a This gross our cash and both diligently extend both prudent in addition, enabled should in up. million proceeds invest guidance that trial couple it weeks clinical GENXXX
expenses same income R&D compared the period for million million to ended period million For in were net XX, the $X.X $X.X $X.X compared same quarter to million December XXXX. G&A and net expenses for fourth to XXXX. for the compared quarter $X.X was million the million were XXXX, a $X.X of $X.X loss
compared R&D million for million net period G&A a $XX.X $XX.X to full-year ended For expenses expenses prior and million $XX.X million the $XX.X rather the were XXXX. of loss to XXXX was net million same were for year the XX, year. $XX.X year for $XX.X loss me to December the forgive for compared compared
maintain company's that to Board approving outstanding the Lastly preliminary and Directors has that adopted to stock statement support effect if a company's of stockholders Genocea stock resolution we’d like common recommending and to reverse necessary proposal intend to we mention proxy listing. in upcoming split a of file Capital a Market the the shortly a which NASDAQ issued
questions. Let's now open up call the Operator? for
